1932
0
  1. Home
  2. A-Z Publications
  3. Annual Review of Clinical Psychology
  4. Volume 10, 2014
  5. Article

Annual Review of Clinical Psychology

Volume 10, 2014

Antidepressant Use in Pregnant and Postpartum Women

Abstract

Women in their reproductive years are at risk of experiencing depressive and anxiety disorders. As such, it is likely that pregnant women will undergo treatment with antidepressants. We review the risk of adverse birth outcomes and neonatal complications subsequent to antidepressant use in pregnancy. An inconsistent literature shows that antidepressant exposure is associated with shortened gestations and diminished fetal growth; these effects are small. Transitory neonatal signs are seen in some neonates after exposure to antidepressants in utero. No specific pattern of malformations has been consistently associated with antidepressants, with the possible exception of paroxetine and cardiac malformations. There is inconclusive evidence of a link between antidepressants in late pregnancy and persistent pulmonary hypertension in the newborn. Extensive study finds that antidepressants cannot be considered major teratogens. It is likely that confounding factors contribute to a number of the adverse effects found to be associated with antidepressant use in pregnancy.

Keyword(s): adverse effects, antidepressants, pregnancy, serotonin reuptake inhibitors, tricyclic antidepressants
Loading

Article metrics loading...

/content/journals/10.1146/annurev-clinpsy-032813-153626
2014-03-28
2024-04-23
Loading full text...

Full text loading...

/deliver/fulltext/clinpsy/10/1/annurev-clinpsy-032813-153626.html?itemId=/content/journals/10.1146/annurev-clinpsy-032813-153626&mimeType=html&fmt=ahah

Literature Cited

  1. Alwan S, Reefhuis J, Botto LD, Rasmussen SA, Correa A. et al. 2010. Maternal use of bupropion and risk for congenital heart defects. Am. J. Obstet. Gynecol. 203:52e1–6 [Google Scholar]
  2. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Natl. Birth Defects Prev. Study 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N. Engl. J. Med. 356:2684–92 [Google Scholar]
  3. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K. et al. 2009. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 18:246–52 [Google Scholar]
  4. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J. et al. 2008. Use of antidepressant medications during pregnancy: a multisite study. Am. J. Obstet. Gynecol. 198:194.e1–5 [Google Scholar]
  5. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res. Part B Dev. Reprod. Toxicol. 80:18–27 [Google Scholar]
  6. Boucher N, Bairam A, Beaulac-Baillargeon L. 2008. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy. J. Clin. Psychopharmacol. 28:334–39 [Google Scholar]
  7. Calderon-Margalit R, Qiu C, Ornoy A, Siscovick DS, Williams MA. 2009. Risk of preterm delivery and other adverse perinatal outcomes in relation to maternal use of psychotropic medications during pregnancy. Am. J. Obstet. Gynecol. 201:579.e1–8 [Google Scholar]
  8. Casper R. 2010. Length of prenatal exposure to selective serotonin reuptake inhibitors (SSRI): effects on neonatal adaptation and psychomotor development. Neuropsychopharmacology 35:S386 [Google Scholar]
  9. Casper RC, Fleisher BE, Lee-Ancajas J, Gilles A, Gaylor E. et al. 2003. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. 142:402–8 [Google Scholar]
  10. Casper RC, Gilles AA, Fleisher BE, Baran J, Enns G, Lazzeroni LC. 2011. Length of prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants: effects on neonatal adaptation and psychomotor development. Psychopharmacology (Berl.) 217:211–19 [Google Scholar]
  11. Chambers CD, Hernandez-Diaz S, Van Marter J, Werler MM, Louik C. et al. 2006. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med. 354:579–87 [Google Scholar]
  12. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. 1996. Birth outcomes in pregnant women taking fluoxetine. N. Engl. J. Med. 335:1010–15 [Google Scholar]
  13. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S. et al. 2005. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am. J. Obstet. Gynecol. 192:932–36 [Google Scholar]
  14. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ. et al. 2006. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. J. Am. Med. Assoc. 295:499–507 [Google Scholar]
  15. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. 2000. Birth outcomes following prenatal exposure to fluoxetine. Biol. Psychiatry 48:996–1000 [Google Scholar]
  16. Cole JA, Ephross SA, Cosmatos IS, Walker AM. 2007a. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf. 16:1075–85 [Google Scholar]
  17. Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, Walker AM. 2007b. Bupropion in pregnancy and the prevalence of congenital malformations. Pharmacoepidemiol. Drug Saf. 16:474–84 [Google Scholar]
  18. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2011. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. [Erratum appears in Birth Defects Res. A. Clin. Mol. Teratol. 2011 Apr;91(4):268.] Birth Defects Res. 91:142–52 [Google Scholar]
  19. Colvin L, Slack-Smith L, Stanley FJ, Bower C. 2012. Early morbidity and mortality following in utero exposure to selective serotonin reuptake inhibitors: a population-based study in Western Australia. CNS Drugs 26:e1–14 [Google Scholar]
  20. Costei A, Kozer E, Ho T, Ito S, Koren G. 2002. Perinatal outcome following third trimester exposure to paroxetine. Arch. Pediatr. Adolesc. Med. 156:1129–32 [Google Scholar]
  21. Croen LA, Grether JK, Yoshida CK, Odouli R, Hendrick V. 2011. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch. Gen. Psychiatry 68:1104–12 [Google Scholar]
  22. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. 2010a. Abortion. See Cunningham et al. 2010c 215–37
  23. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. 2010b. Teratology and medications that affect the fetus. See Cunningham et al. 2010c 312–33
  24. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY. 2010c. Williams Obstetrics. New York: McGraw Hill
  25. Dahl M, Olhager E, Ahlner J. 1997. Paroxetine withdrawal syndrome in a neonate. Br. J. Psychiatry 171:391–92 [Google Scholar]
  26. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE. et al. 2007. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol. Drug Saf. 16:1086–94 [Google Scholar]
  27. Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M. et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br. J. Clin. Pharmacol. 66:695–705 [Google Scholar]
  28. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S. et al. 2006. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes. J. Clin. Psychiatry 67:1280–84 [Google Scholar]
  29. Einarson A. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am. J. Psychiatry 158:1728–30 [Google Scholar]
  30. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D. et al. 2003. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Can. J. Psychiatry 48:106–10 [Google Scholar]
  31. Einarson A, Choi J, Einarson TR, Koren G. 2009. Rates of spontaneous and therapeutic abortions following use of antidepressants in pregnancy: results from a large prospective database. J. Obstet. Gynaecol. Can. 31:452–56 [Google Scholar]
  32. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J. et al. 2001. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am. J. Psychiatry 158:1728–30 [Google Scholar]
  33. El Marroun H, Jaddoe VWV, Hudziak JJ, Roza SJ, Steegers EAP. et al. 2012. Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch. Gen. Psychiatry 69:706–14 [Google Scholar]
  34. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M. et al. 2007. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 119:52–59 [Google Scholar]
  35. Gavin N, Gaynes B, Lohr K, Meltzer-Brody S, Gartlehner G, Swinson T. 2005. Perinatal depression: a systematic review of prevalence and incidence. Obstet. Gynecol. 106:1071–83 [Google Scholar]
  36. Gentile S. 2010. Antipsychotic therapy during early and late pregnancy. A systematic review. Schizophr. Bull. 36:518–44 [Google Scholar]
  37. Graves ED 3rd, Redmond CR, Arensman RM. 1988. Persistent pulmonary hypertension in the neonate. Chest 93:638–41 [Google Scholar]
  38. Greene MF. 2007. Teratogenicity of SSRIs—serious concern or much ado about little?. N. Engl. J. Med. 356:2732–33 [Google Scholar]
  39. Grigoriadis S, VonderPorten EH, Mamisashvili L, Roerecke M, Rehm J. et al. 2013. Antidepressant exposure during pregnancy and congenital malformations: Is there an association? A systematic review and meta-analysis of the best evidence. J. Clin. Psychiatry 74:e293–308 [Google Scholar]
  40. Grzeskowiak LE, Gilbert AL, Morrison JL. 2012. Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J. Clin. Psychopharmacol. 32:615–21 [Google Scholar]
  41. Haddad PM, Pal BR, Clarke P, Wieck A, Sridhiran S. 2005. Neonatal symptoms following maternal paroxetine treatment: serotonin toxicity or paroxetine discontinuation syndrome?. J. Psychopharmacol. 19:554–57 [Google Scholar]
  42. Hayes RM, Wu P, Shelton RC, Cooper WO, Dupont WD. et al. 2012. Maternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies. Am. J. Obstet. Gynecol. 207:49.e1–9 [Google Scholar]
  43. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. 2005. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann. Pharmacother. 39:803–9 [Google Scholar]
  44. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. 2003. Placental passage of antidepressant medications. Am. J. Psychiatry 160:993–96 [Google Scholar]
  45. Hernández-Díaz S, Van Marter LJ, Werler MM, Louik C, Mitchell AA. 2007. Risk factors for persistent pulmonary hypertension of the newborn. Pediatrics 120:e272–82 [Google Scholar]
  46. Jimenez-Solem E, Andersen JT, Petersen M, Broedbaek K, Jensen JK. et al. 2012. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2:e001148 [Google Scholar]
  47. Källén B. 2004. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch. Pediatr. Adolesc. Med. 158:312–16 [Google Scholar]
  48. Källén B, Olausson PO. 2008. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol. Drug Saf. 17:801–6 [Google Scholar]
  49. Källén BAJ, Otterblad Olausson P. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res. 79:301–8 [Google Scholar]
  50. Kessler R, McGonagle K, Zhao S, Nelson C, Hughes M. et al. 1994. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51:8–19 [Google Scholar]
  51. Kieler H, Artama M, Engeland A, Ericsson O, Furu K. et al. 2012. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 344:d8012 [Google Scholar]
  52. Klieger-Grossmann C, Weitzner B, Einarson T, Koren G, Einarson A. 2010. The safety of escitalopram in pregnancy: a prospective cohort study. J. Popul. Ther. Clin. Pharmacol. 17:1e230 [Google Scholar]
  53. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. 2010. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin. Epidemiol. 2:29–36 [Google Scholar]
  54. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G. et al. 1998. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. J. Am. Med. Assoc. 279:8609–10 [Google Scholar]
  55. Laine K, Heikkinen T, Ekblad U, Kero P. 2003. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60:720–26 [Google Scholar]
  56. Lauder JM. 1993. Neurotransmitters as growth regulatory signals: role of receptors and second messengers. Trends Neurosci. 16:233–40 [Google Scholar]
  57. Lawn JE, Blencowe H, Pattinson R, Cousens S, Kumar R. et al. 2011. Stillbirths: Where? When? Why? How to make the data count?. Lancet 377:1448–63 [Google Scholar]
  58. Lennestal R, Källén B. 2007. Delivery outcome in relation to maternal use of some recently introduced antidepressants. J. Clin. Psychopharmacol. 27:607–13 [Google Scholar]
  59. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ. et al. 2006. Antidepressants in amniotic fluid: another route of fetal exposure. Am. J. Psychiatry 163:145–47 [Google Scholar]
  60. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N. Engl. J. Med. 356:2675–83 [Google Scholar]
  61. Lund N, Pedersen LH, Henriksen TB. 2009. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch. Pediatr. Adolesc. Med. 163:949–54 [Google Scholar]
  62. Malm H, Artama M, Gissler M, Ritvanen A. 2011. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstetr. Gynecol. 118:111–20 [Google Scholar]
  63. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. 2007. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study. BJOG 115:283–89 [Google Scholar]
  64. Misri S, Reebye P, Kendrick K, Carter D, Ryan D. et al. 2006. Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications. Am. J. Psychiatry 163:1026–32 [Google Scholar]
  65. Mitchell AA, Gilboa SM, Werler MM, Kelley KE, Louik C, Hernández-Díaz S. 2011. Medication use during pregnancy, with particular focus on prescription drugs: 1976–2008. Am. J. Obstet. Gynecol. 205:51.e1–8 [Google Scholar]
  66. Moses-Kolko E, Bogen D, Perel J, Bregar A, Uhl K. et al. 2005. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications. J. Am. Med. Assoc. 293:2372–83 [Google Scholar]
  67. Munk-Olsen T, Laursen TM, Pedersen CB, Mors O, Mortensen PB. 2006. New parents and mental disorders: a population-based register study. JAMA 296:2582–89 [Google Scholar]
  68. Nakhai-Pour HR, Broy P, Berard A. 2010. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can. Med. Assoc. J. 182:1031–37 [Google Scholar]
  69. Nikfar S, Abdollahi M, Hendoiee N, Rahimi R. 2012a. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis. Value Health 15:7A638 [Google Scholar]
  70. Nikfar S, Rahimi R, Hendoiee N, Abdollahi M. 2012b. Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: a systematic review and updated meta-analysis. DARU J. Pharm. Sci. 20:75 [Google Scholar]
  71. Nordeng H, Spigset O. 2005. Treatment with selective serotonin reuptake inhibitors in the third trimester of pregnancy. Drug Saf. 28:565–81 [Google Scholar]
  72. Nordeng H, van Gelder MM, Spigset O, Koren G, Einarson A, Eberhard-Gran M. 2012. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian Mother and Child Cohort Study. J. Clin. Psychopharmacol. 32:186–94 [Google Scholar]
  73. Nulman I, Koren G, Rovet J, Barrera M, Pulver A. et al. 2012. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression. Am. J. Psychiatry 169:1165–74 [Google Scholar]
  74. Nulman I, Rovet J, Stewart D, Wolpin J, Pace-Asciak P. et al. 2002. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159:1889–95 [Google Scholar]
  75. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA. et al. 1997. Neurodevelopment of children exposed in utero to antidepressant drugs. N. Engl. J. Med. 336:258–62 [Google Scholar]
  76. Oberlander TF, Misri S, Fitzgerald CE, Kostsaras X, Rurak D, Riggs W. 2004. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J. Clin. Psychiatry 65:230–37 [Google Scholar]
  77. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J. et al. 2007. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch. Pediatr. Adolesc. Med. 161:22–29 [Google Scholar]
  78. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. 2006. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch. Gen. Psychiatry 63:898–906 [Google Scholar]
  79. Oberlander TF, Warburton W, Misri S, Riggs W, Aghajanian J, Hertzman C. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res. Part B Dev. Reprod. Toxicol. 83:68–76 [Google Scholar]
  80. Occhiogrosso M, Omran SS, Altemus M. 2012. Persistent pulmonary hypertension of the newborn and selective serotonin reuptake inhibitors: lessons from clinical and translational studies. Am. J. Psychiatry 169:134–40 [Google Scholar]
  81. Pacifici GM, Nottoli R. 1995. Placental transfer of drugs administered to the mother. Clin. Pharmacokinet. 28:235–69 [Google Scholar]
  82. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M. et al. 1993. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). J. Am. Med. Assoc. 269:172246–48 [Google Scholar]
  83. Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF. et al. 2007. Birth outcomes following prenatal exposure to antidepressants. J. Clin. Psychiatry 68:1284–89 [Google Scholar]
  84. Pedersen LH, Henriksen TB, Olsen J. 2010. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 125:e600–8 [Google Scholar]
  85. Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. 2009. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339:b3569 [Google Scholar]
  86. Polen KND, Rasmussen SA, Riehle-Colarusso T, Reefhuis J. 2013. Association between reported venlafaxine use in early pregnancy and birth defects, national birth defects prevention study, 1997–2007. Birth Defects Res. A Clin. Mol. Teratol. 97:28–35 [Google Scholar]
  87. Rai D, Lee BK, Dalman C, Golding J, Lewis G, Magnusson C. 2013. Parental depression, maternal antidepressant use during pregnancy, and risk of autism spectrum disorders: population based case-control study. BMJ 97:28–35 [Google Scholar]
  88. Ramos E, St-Andre M, Berard A. 2010. Association between antidepressant use during pregnancy and infants born small for gestational age. Can. J. Psychiatry Rev. Can. Psychiatr. 55:643–52 [Google Scholar]
  89. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. 2008. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br. J. Psychiatry 192:344–50 [Google Scholar]
  90. Rampono J, Simmer K, Ilett KF, Hackett LP, Doherty DA. et al. 2009. Placental transfer of SSRI and SNRI antidepressants and effects on the neonate. Pharmacopsychiatry 42:95–100 [Google Scholar]
  91. Reis M, Källén B. 2010. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol. Med. 40:1723–33 [Google Scholar]
  92. Roca A, Garcia-Esteve L, Imaz ML, Torres A, Hernandez S. et al. 2011. Obstetrical and neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitors: the relevance of dose. J. Affect. Disord. 135:208–15 [Google Scholar]
  93. Ross L, Grigoriadis S, Mamisashvili L, Vonderporten EH, Roerecke M. et al. 2013. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry 70:436–43 [Google Scholar]
  94. Sanz E, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. 2005. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365:482–87 [Google Scholar]
  95. Saunders NR, Ek CJ, Habgood MD, Dziegielewska KM. 2008. Barriers in the brain: a renaissance?. Trends Neurosci. 31:279–86 [Google Scholar]
  96. Simon GE, Cunningham ML, Davis RL. 2002. Outcomes of prenatal antidepressant exposure. Am. J. Psychiatry 159:2055–61 [Google Scholar]
  97. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. 2005. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome. Am. J. Obstet. Gynecol. 193:2004–9 [Google Scholar]
  98. Smith MV, Sung A, Shah B, Mayes L, Klein DS, Yonkers KA. 2013. Neurobehavioral assessment of infants born at term and in utero exposure to serotonin reuptake inhibitors. Early Hum. Dev. 89:81–86 [Google Scholar]
  99. Spencer M. 1993. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 92:721–22 [Google Scholar]
  100. Spong CY, Reddy UM, Willinger M. 2011. Addressing the complexity of disparities in stillbirths. Lancet 377:1635–36 [Google Scholar]
  101. Stephansson O, Kieler H, Haglund B, Artama M, Engeland A. et al. 2013. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 309:48–54 [Google Scholar]
  102. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. 2007. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am. J. Psychiatry 164:1206–13 [Google Scholar]
  103. Suri R, Hellemann G, Stowe ZN, Cohen LS, Aquino A, Altshuler LL. 2011. A prospective, naturalistic, blinded study of early neurobehavioral outcomes for infants following prenatal antidepressant exposure. J. Clin. Psychiatry 72:1002–7 [Google Scholar]
  104. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez-Diaz S. 2009. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J. Clin. Psychopharmacol. 29:555–60 [Google Scholar]
  105. Vesga-Lopez O, Blanco C, Keyes K, Olfson M, Grant BF. et al. 2008. Psychiatric disorders in pregnant and postpartum women in the United States. Arch. Gen. Psychiatry 65:805–15 [Google Scholar]
  106. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB. et al. 2000. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14–20 [Google Scholar]
  107. Warburton W, Hertzman C, Oberlande TF. 2010. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr. Scand. 121:471–79 [Google Scholar]
  108. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O. et al. 2006. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am. J. Obstet. Gynecol. 194:961–66 [Google Scholar]
  109. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH Jr, Watson WJ. 2009. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin. Proc. 84:23–27 [Google Scholar]
  110. Wilson KL, Zelig CM, Harvey JP, Cunningham BS, Dolinsky BM, Napolitano PG. 2011. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am. J. Perinatol. 28:19–24 [Google Scholar]
  111. Wisner KL. 2011. Impact of SSRI antidepressants and major depression on pregnancy and infant outcomes. Arch. Women's Ment. Health 14:S113 [Google Scholar]
  112. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL. et al. 2009. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am. J. Psychiatry 166:557–66 [Google Scholar]
  113. World Health Organ 1992. International Statistical Classification of Diseases and Related Health Problems Geneva: WHO, 10th rev..
  114. Wurst KE, Poole C, Ephross SA, Olshan AF. 2010. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res. 88:159–70 [Google Scholar]
  115. Yonkers K, Wisner K, Stewart D, Oberlander T, Dell D. et al. 2009. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen. Hosp. Psychiatry 31:403–13 [Google Scholar]
  116. Yonkers KA, Gotman N, Smith MV, Forray A, Belanger K. et al. 2011. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy?. Epidemiology 22:848–54 [Google Scholar]
  117. Yonkers KA, Norwitz ER, Smith MV, Lockwood CJ, Gotman N. et al. 2012. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology 23:677–85 [Google Scholar]
  118. Yonkers KA, Wisner KL, Stowe Z, Leibenluft E, Cohen L. et al. 2004. Management of bipolar disorder during pregnancy and the postpartum period. Am. J. Psychiatry 161:608–20 [Google Scholar]
  119. Zeskind P, Stephens L. 2004. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 113:368–75 [Google Scholar]
/content/journals/10.1146/annurev-clinpsy-032813-153626
Loading
  • Article Type: Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error